BACKGROUND: Studies in traumatic brain injury suggest that monitoring techniques such as brain tissue oxygen (PBTO 2 ) and cerebral microdialysis may complement conventional intracranial pressure (ICP) and cerebral perfusion pressure (CPP) measurements. OBJECTIVE: In this study of poor-grade (Hunt and Hess grade IV and V) subarachnoid hemorrhage (SAH) patients, we examined the prevalence of brain hypoxia and brain energy dysfunction in the presence of normal and abnormal ICP and CPP. METHODS: SAH patients who underwent multimodal neuromonitoring and cerebral microdialysis were studied. We examined the frequency of brain hypoxia and energy dysfunction in different ICP and CPP ranges and the relationship between PBTO 2 and the lactate/pyruvate ratio (LPR). RESULTS: A total of 2394 samples from 19 patients were analyzed. There were 149 samples with severe brain hypoxia (PBTO 2 #10 mm Hg) and 347 samples with brain energy dysfunction (LPR .40). The sensitivities of abnormal ICP or CPP for elevated LPR and reduced PBTO 2 were poor (21.2% at best), and the LPR or PBTO 2 was abnormal in many instances when ICP or CPP was normal. Severe brain hypoxia was often associated with an LPR greater than 40 (86% of samples). In contrast, mild brain hypoxia (#20 mm Hg) and severe brain hypoxia were observed in only 53% and 36% of samples with brain energy dysfunction, respectively. CONCLUSION: Our data demonstrate that ICP and CPP monitoring may not always detect episodes of cerebral compromise in SAH patients. Our data suggest that several complementary monitors may be needed to optimize the care of poor-grade SAH patients.
A fundamental goal in neurocritical care is the detection and treatment of secondary cerebral insults, in particular, cerebral ischemia and hypoxia. In part, this is achieved through neuromonitoring. Recent evidence, however, suggests that conventional neuromonitoring using intracranial pressure (ICP) and cerebral perfusion pressure (CPP) thresholds may miss some episodes of cerebral compromise. Studies done primarily in patients with traumatic brain injury (TBI) demonstrate that brain hypoxia and ischemia can occur despite normal ICP and CPP. [1] [2] [3] [4] Newer monitoring techniques that use brain tissue oxygen (PBTO 2 ) electrodes and cerebral microdialysis (CMD) catheters may complement ICP and CPP monitoring in severe TBI and subarachnoid hemorrhage (SAH). [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] How best to integrate the information provided by each monitor remains unclear and has been better studied in TBI than in aneurysmal SAH. In the current study, we examined the relationship between ICP, CPP, PBTO 2 , and energy metabolites derived from CMD in SAH patients. In particular, we asked whether brain energy dysfunction and brain hypoxia occur when ICP and CPP are normal.
CLINICAL MATERIALS AND METHODS

Patient Sample
This study included patients admitted between March 2005 and November 2007 to the Hospital of the University of Pennsylvania, a level I, university-affiliated trauma center and Joint Commission on Accreditation of Healthcare Organizations-certified stroke center who were recruited into a prospective observational study of CMD in SAH. Informed consent to enroll in this study was obtained from patients, their families, or legal representatives. Inclusion criteria included (1) SAH confirmed by computed tomography (CT) scan of the head or lumbar puncture, (2) an aneurysm defined by digital subtraction angiography (DSA), (3) admission and aneurysm occlusion within 3 days of aneurysm rupture, and (4) simultaneous intracranial monitoring using an ICP monitor, PBTO 2 electrode, and CMD. Our standard practice is to monitor all SAH patients with a Glasgow Coma Scale (GCS) score of 8 or less with an ICP and PBTO 2 monitor. CBM catheters were placed only if patients' family members or legal representatives consented to the research project. Exclusion criteria included (1) pregnancy, (2) coagulopathy, (3) central nervous system infection on admission, (4) bilateral fixed and dilated pupils at admission or impending (,24 hours) brain death, (5) nonaneurysmal SAH, and (6) rebleeding. Patients included in the analysis described in this study were retrospectively identified from a prospective observational database with institutional review board approval.
Patient Management
Patients were managed in the Neurointensive Care Unit (NeuroICU) using a local protocol based on published recommendations for SAH. 18, 19 This included (1) intubation and mechanical ventilation when the GCS score was 8 or less; (2) adjustment of fraction of inspired oxygen (FIO 2 ), minute ventilation, and positive-end expiratory pressure to maintain arterial oxygen saturation greater than 93%, and to avoid PaO 2 less than 60 mm Hg; (3) maintenance of PaCO 2 between 35 and 45 mm Hg for normal ICP and 30 to 40 mm Hg for elevated ICP; (4) placement of an external ventricular drain for symptomatic hydrocephalus; (5) maintenance of systolic blood pressure between 100 and 200 mm Hg and central venous pressure between 6 and 8 mm Hg; (6) glycemic control (blood glucose 90-130 mg/dL); (7) seizure prophylaxis for 1 week unless seizures developed; (8) nimodipine administration; and (9) the use of statins (simvastatin 80 mg/day). All patients underwent aneurysm occlusion within 24 hours of admission. The decision to clip or coil an aneurysm was based on its morphology and location. Each patient underwent nonenhanced head CT scans 24 hours after admission, after aneurysm occlusion, and when clinically indicated. Daily transcranial Doppler measurements of cerebral blood flow (CBF) velocities were performed, and follow-up DSA was performed 7 days after aneurysm occlusion and when clinically indicated.
ICP Management
Therapeutic targets were adjusted to avoid ICP greater than 20 mm Hg and CPP less than 60 mm Hg. A standard stepwise approach was used to treat elevated ICP (.20 mm Hg). Initial management included elevating the head (20-30 degrees), sedation (eg, lorazepam), analgesia (eg, fentanyl), intermittent cerebrospinal fluid drainage through a ventriculostomy, and moderate hyperventilation. If ICP remained greater than .20 mm Hg for more than 10 to 15 minutes despite this initial management, osmotherapy (mannitol) was started, provided that serum osmolarity was less than 320 mOsm/L and serum sodium was less than 155 mmol/L. Second-tier therapies included decompressive craniectomy or additional sedation with propofol or barbiturates.
Brain Oxygen Management
Patients received ''cause''-directed therapy to maintain PBTO 2 of 20 mm Hg or more, 20, 21 consistent with current National Institutes of Health-funded trials that examine PBTO 2 -based care in TBI. There are many therapies to correct PBTO 2 , 22,23 but the following basic protocol is used in our NeuroICU. When PBTO 2 was low and ICP was elevated, measures were taken to lower ICP as described previously. If ICP was not high or lowering ICP failed to increase PBTO 2 , then CPP was increased, usually with phenylephrine. Nicardipine to correct hyperemia was considered next if PBTO 2 continued to be low. If the cause of brain hypoxia was systemic hypoxia, pulmonary function was optimized by adjusting ventilator settings (eg, increasing FIO 2 and/or positive end-expiratory pressure). If excess metabolic demand was suspected because of pain, agitation, fever, or seizures, the appropriate medications to counteract this demand were administered. If these measures failed and the patient's hemoglobin was less than 10 mg/dL, transfusion of packed red blood cells was considered. A decompressive craniectomy was performed if intractable elevated ICP despite maximal medical management led to progressive or sustained PBTO 2 decline.
Management of Delayed Cerebral Ischemia
Patients in whom delayed cerebral ischemia (DCI) developed, thought to be associated with vasospasm, were treated with euvolemia, induced hypertension using vasopressors to obtain a systolic blood pressure greater than 180 mm Hg or more than 20% above baseline, and endovascular intervention (usually balloon angioplasty) if symptoms persisted despite induced hypertension. The diagnosis of DCI and the subsequent decision to perform DSA was based on several factors, often in combination, including (1) neurological worsening (based on the GCS score and National Institutes of Health Stroke Scale), (2) a persistent PBTO 2 less than 15 mm Hg in sedated and paralyzed patients and no other identifiable cause, (3) elevated transcranial Doppler readings (ie, middle cerebral artery blood flow velocity .180 cm/s), (4) decreased alpha variability on continuous electroencephalography when used, and (5) reduced blood flow on CT perfusion imaging.
Cerebral Microdialysis
For CMD, CMA-70 probes (CMA Microdialysis, Stockholm, Sweden) with 10-mm dialysis membranes (20-kDa cutoff) were used. The CMA 106 perfusion pump (CMA Microdialysis, Solna, Sweden) was used to perfuse the catheters with sterile, room-temperature artificial cerebrospinal fluid at a rate of 0.3 mL/min. Microdialysis samples were collected every 60 minutes and analyzed for glucose, lactate, and pyruvate (CMA 600; CMA). The analyzer was automatically calibrated at the outset and every 6 hours using standard calibration solutions.
Placement of Intracranial Monitors
Intracranial monitors (ICP, PBTO 2 , and CMD) were inserted simultaneously at the bedside through a burr hole in the frontal lobe and secured with the same triple-lumen bolt. Monitors were placed into normal-appearing white matter on admission head CT scans on the side of maximal pathology (ie, maximal SAH) and at the border zone between the anterior and middle cerebral artery territories. The probes were allowed to stabilize for 1 to 2 hours before use. Brain oxygen probe function and stability were confirmed by an appropriate PBTO 2 increase after an oxygen challenge (FIO 2 of 1.0 for 5 minutes). A noncontrast head CT scan was performed to confirm probe placement in normalappearing white matter. Intracranial monitors were removed when ICP remained less than 20 mm Hg for 24 hours without specific treatment other than sedation for ventilator management.
Physiological Monitors and Data Collection
CP and PBTO 2 were continuously monitored using commercially available products (Licox; Integra Neuroscience, Plainsboro, New Jersey). Heart rate, arterial line and central venous blood pressures, and arterial oxygen saturation (SaO 2 ) were monitored continuously (Component Monitoring System M1046-9090C; Hewlett Packard, Andover, Massachusetts). Cerebral perfusion pressure was calculated from measured parameters (CPP = mean arterial pressure 2 ICP). The mean arterial pressure was derived from arterial lines with transducers leveled at the phlebostatic axis.
Values for heart rate, blood pressure, SaO 2 , ICP, brain temperature, PBTO 2 , central venous pressure, and FIO 2 were recorded, on average, every 15 minutes on NeuroICU nursing flow sheets. These values were averaged every hour for comparison with CMD lactate, pyruvate, and glucose data that were extracted from microdialysis flow sheets on an hourly basis. Eight-hour fluid balance also was extracted from NeuroICU flow sheets. Values for hemoglobin; white blood cell count; serum sodium, creatinine, and glucose; blood urea nitrogen; and arterial pH and PaO 2 were obtained from electronic medical records.
Statistical Analysis
Statistical analysis was performed using SPSS 16 software (SPSS Inc., Chicago Illinois). The data are summarized as the mean 6 standard deviation unless otherwise stated. Univariate analysis of pooled data was performed with the Student t test and Wilcoxon rank-sum (MannWhitney test) for continuous parametric and nonparametric variables, respectively, and the x 2 test (or Fisher exact test) for categorical variables. Sensitivities and specificities were calculated according to standard equations using constructed 2 3 2 matrices. Sensitivity was calculated as the periods of abnormal brain oxygen or LPR, however defined, detected by the threshold parameter divided by the total of number of such periods. Specificity was calculated as the periods of normal brain oxygen or LPR not detected by the threshold parameter divided by the total of number of such periods. Brain tissue hypoxia was defined as mild (PBTO 2 ,20 mm Hg), moderate (PBTO 2 ,15 mm Hg), and severe (PBTO 2 ,10 mm Hg). Brain energy dysfunction was defined by an LPR greater than 40 in the cerebral microdialysate. 24, 25 Periods of abnormal cerebral physiology longer than 5 consecutive minutes were recorded as such. The terms normal and abnormal are used to describe parameters relative to their respective treatment thresholds. They do not necessarily imply that a specific value is physiologically normal or abnormal. A P value ,.05 was considered statistically significant.
RESULTS
Patient Characteristics
Nineteen consecutive patients with aneurysmal SAH who were monitored using ICP/CPP monitors, PBTO 2 electrodes, and CBM were studied. The clinical and radiographic characteristics of these patients are described in Table 1 . At the time of admission, 14 (74%) had a poor clinical grade (Hunt and Hess grade IV or V). These patients had their monitors inserted at the time of admission. The remaining patients deteriorated after admission. At the time of intracranial monitoring, all patients had a Glasgow Coma Scale score of 8 or less. Multimodal monitoring was started 1.4 6 0.9 days after admission and lasted 5.8 6 1.8 days. Time to monitor insertion was similar in patients who underwent surgical or endovascular aneurysm occlusion. A total of 2394 samples of combined data were collected and analyzed. This data set included 2183 ICP, 2179 CPP, 2172 PBTO 2 , and 2133 CBM samples. Relationship of ICP and CPP With Brain Hypoxia and Metabolic Dysfunction A total of 235 separate samples with intracranial hypertension (ICP $20 mm Hg for .5 minutes) were identified in the 19 patients. These samples with increased ICP were associated with significantly lower mean CPP and PBTO 2 than when ICP was normal (,20 mm Hg) ( Table 2 ). In 55.6% of the samples with increased ICP, CPP was less than 60 mm Hg. In contrast, reduced CPP was very rare when ICP was normal (7.9%) ( Figure 1A) . In some samples with elevated ICP, PBTO 2 was between 10 and 20 mm Hg (35 samples, 14.8%) or less than 10 mm Hg (29 samples, 12.3%); however, during most episodes of elevated ICP, PBTO 2 was more than 20 mm Hg (161 samples, 68.5%; Figure 1B ). In addition, the overall mean PBTO 2 was within the normal range during episodes of increased ICP ( Table 2 ). The mean LPR was similar among patients with normal or elevated ICP (Table 2 ). In addition, the number of samples with an LPR greater than 40 was similar when the ICP was less than 20 mm Hg (15.0%) and 20 mm Hg or greater (14.5%) ( Figure 1C) . Figure 2 illustrates the relationships between CPP and ICP and PBTO 2 and LPR. There were 133 samples (5.6%) with reduced CPP (,60 mm Hg). When CPP was less than 60 mm Hg, increased ICP was common (Figure 2A ). In addition, the mean PBTO 2 was significantly lower and the mean LPR was significantly higher than when CPP was greater than 60 mm Hg (Table 3) . However, when CPP was reduced, brain hypoxia and brain energy dysfunction were not common ( Figure 2B ). When CPP was less than 60 mm Hg, brain hypoxia (51.9% of samples) and brain energy dysfunction (69.2% of samples) were usually absent.
Compromised PBTO 2 and Brain Hypoxia
A total of 180 samples with mild and moderate brain hypoxia (10-20 mm Hg) and 149 samples with severe brain hypoxia (PBTO 2 ,10 mm Hg) were identified during the monitoring period. A total of 145 samples (80.6%) with mild brain hypoxia and 118 samples (79.2%) with severe brain hypoxia were associated with normal ICP. The mean ICP (6 standard deviation [SD]) during normoxia (.20 mm Hg), mild brain hypoxia, and severe brain hypoxia was 10.6 6 7.4 mm Hg, 11.5 6 9.9 mm Hg, Increased LPR A total of 347 (14.5%) samples with an increased LPR consistent with brain energy dysfunction (LPR .40) were identified, and 117 of these samples also were characterized with severe brain hypoxia. ICP was normal in 293 of the samples (84.4%). The mean ICP (6 SD) during brain energy dysfunction and when the LPR was less than 40 were 11.7 6 11.9 mm Hg and 10.5 6 8.2 mm Hg, respectively (P = .06). In these same samples, the mean CPP (6 SD) was 80.2 6 32.2 mm Hg and 92.7 6 31.8 mm Hg (P , .001). CPP was normal in 283 (81.6%) of the samples with concurrent brain energy dysfunction.
Systemic Oxygenation and PBTO 2 and LPR
Available for analysis were 307 simultaneous PBTO 2 , LPR, and PaO 2 samples. The mean PaO 2 was 138 6 75 mm Hg. In 20 samples (6.5%), PaO 2 was less than 60 mm Hg. The mean PBTO 2 in this group did not differ significantly from the mean PBTO 2 in samples with normal systemic oxygenation (Table 4) . Interestingly, the mean LPR was higher in samples with normal systemic oxygenation. Focusing on the samples with evidence of any degree of brain hypoxia (PBTO 2 ,20 mm Hg), the mean LPR with normal systemic oxygenation (75 6 54, n = 69) was again higher compared with the LPR with low systemic oxygenation (56 6 24, n = 4). However, this difference was not statistically significant (P = .22).
We next examined PBTO 2 and LPR using the PaO 2 /FIO 2 ratio as a surrogate for lung function. Using the standard definition of acute lung injury (PaO 2 /FIO 2 ratio ,300), we identified 193 samples (62.9%) in which lung function was impaired. The mean PBTO 2 was significantly lower and the mean LPR was significantly higher in the setting of acute lung injury (Table 4) . Again examining the samples associated with brain hypoxia, the mean LPR tended to be higher when lung function was impaired (78 6 56, n = 55) compared with normal lung function (61 6 40, n = 18; P = .15). These data suggest that poor lung function, although not systemic oxygenation in general, is associated with poor cerebral oxygenation and metabolism. Tables 4 and 5 illustrate the sensitivity and specificity of ICP and CPP for various PBTO 2 (Table 5) and LPR (Table 6) thresholds. Together, these data suggest that an ICP of 20 mm Hg or more and a CPP less than 60 mm Hg are fairly specific for abnormal PBTO 2 and an increased LPR but are not sensitive.
Sensitivity and Specificity of ICP and CPP for Brain Hypoxia or Brain Energy Dysfunction
Comparison of PBTO 2 and LPR Data
We next examined the relationship between PBTO 2 and brain energy dysfunction. When there was severe brain hypoxia, brain energy dysfunction was frequent and occurred concurrently in 86% of the episodes of brain hypoxia. Similarly, the LPR was greater than 40 during most episodes of mild brain hypoxia ( Figure 3A) . In contrast, PBTO 2 levels were normal (.20 mm Hg) in approximately half of the episodes of brain energy dysfunction ( Figure 3B ). The interrelationship between PBTO 2 and LPR is further summarized in Table 6 as sensitivities and specificities. These data suggest that there may be 2 distinct patterns of disturbed metabolic function in SAH patients, one associated with compromised PBTO 2 and the other with normal PBTO 2 .
Mortality, PBTO 2 , and LPR
Thirty-day survival was assessed. At this time, 7 patients (37%) had died. Compared with patients who died, the mean PBTO 2 was significantly greater and the LPR was significantly lower in patients who survived (Table 7) . Both patterns of brain energy dysfunction occurred more frequently in patients who died. Brain hypoxia was more commonly associated with brain energy dysfunction in patients who died than those who survived (64% vs 36%, P , .001).
DISCUSSION
In this study, we examined ICP, CPP, PBTO 2 , and cerebral glucose metabolism using microdialysis in 19 poor-grade SAH patients. Our results suggest that conventional measures of cerebral compromise (ie, ICP $20 mm Hg, CPP ,60 mm Hg) may not identify all episodes of brain hypoxia and energy dysfunction. From pooled data, the mean PBTO 2 was lower and the mean LPR was higher with intracranial hypertension and depressed CPP. Low PBTO 2 and a high LPR also were more frequently observed during periods of high ICP and low CPP.
However, sensitivity analysis demonstrated that usual treatment thresholds for ICP and CPP were not associated with a majority of the episodes of brain hypoxia and brain energy dysfunction. At best, a CPP less than 60 mm Hg correlated with only 21.2% of the hours when PBTO 2 15 mm Hg or less (Table 5 ). These data suggest that a combination of monitors may be necessary to detect episodes of cerebral compromise in patients with poorgrade aneurysmal SAH. Because several periods of intracranial hypertension and low CPP were not associated with brain hypoxia or energy dysfunction, PBTO 2 monitors and CBM should be regarded as complementary tools to ICP/CPP monitoring. In addition, there appear to be at least 2 types of brain energy dysfunction after SAH, one associated with normoxia and the other with hypoxia. This finding is consistent with results in TBI patients, in whom both ischemic and nonischemic episodes of an increased LPR are observed. 24 Further studies are needed to identify specific patterns of cerebral compromise based on the various monitoring techniques and to correlate these patterns with clinical events and interventions. Moreover, prospective studies are needed to demonstrate that interventions for abnormal physiological parameters improve patient outcomes.
Conventional Cerebral Monitoring
An ICP monitor is considered the gold standard in neurocritical care. CPP is estimated from the ICP and mean arterial pressure. Because CPP is a major determinant of CBF, increases in ICP or decreases in CPP may be a determinant of cerebral ischemia. However, several recent clinical studies using jugular venous catheters or PBTO 2 monitors suggest that cerebral ischemia can occur despite normal ICP and CPP values and that optimized ICP and CPP may not prevent brain hypoxia. 3, 4, 26, 27 Positron emission topography studies in human TBI patients suggest that brain hypoxia is associated with an oxygen diffusion defect rather than an abnormality in perfusion. 28 Microdialysis studies in TBI indicate that changes in the LPR may precede the onset of intracranial hypertension 29 and that increased pericontusional LPR is not associated with CPP. 30 These pathophysiological findings may help to explain why therapies that improve CPP do not always improve patient outcomes. [31] [32] [33] Most previous work in this area has been in TBI patients. Our results are consistent with and extend these observations and suggest that ICP and CPP data may not always identify compromised brain physiology in comatose patients after SAH. 
Brain Oxygen in SAH
Monitoring for and treating vasospasm and decreased has been the primary focus of neurocritical care after aneurysmal SAH. Brain oxygen values, however, do not directly measure CBF. Instead, they provide an estimate of the interaction among substrate delivery, extraction, and demand 34 or may represent oxygen diffusion, described by the relationship PBTO 2 = CBF 3 arteriovenous oxygen tension difference, 35 rather than metabolism. Although the exact determinants of PBTO 2 are still being elucidated, it is clear that compromised PBTO 2 (ie, ,20 mm Hg) is not a benign process. It indicates the presence of a pathophysiological process (eg, cerebral, cardiorespiratory, systemic) and should prompt a search for its etiology. For example, our data demonstrate that lung injury was associated with lower PBTO 2 .
Other clinical studies have observed a relationship between PBTO 2 and measures of substrate delivery, including CBF, 36 PaO 2 , 37 and hemoglobin. 38 Decreased PBTO 2 , however, may not always indicate ischemia. In other words, a PBTO 2 monitor is not a monitor of vasospasm. 34, 39 A PBTO 2 threshold that represents ischemia has been difficult to define, although oxygen extraction studies suggest that PBTO 2 values less than 15 mm Hg may be associated with ischemia. 40 Brain oxygen monitors have been used successfully in SAH to complement ICP and CPP monitors in detecting ischemia 11, 41 and to help predict poor patient outcome. 10, 42 In addition, PBTO 2 monitors may be used to help direct CPP-oriented therapies 9 and to assess the efficacy of therapeutic interventions such as induced hypertension and hypervolemia, 43 ,44 blood transfusion, 38 and nimodipine. 45 The concept of tissue oxygen reactivity and its relationship to cerebrovascular autoregulation and tissue infarction also has generated interest, 34, 46 although a recent study did not find any difference in autoregulatory indices between patients with and without evidence of SAH-associated cerebral infarcts. 47 
CBM in SAH
CMD quantifies levels of interstitial metabolites and can be used to evaluate cellular function and dysfunction. The most widely used and studied marker is the LPR. 48, 49 The LPR reflects the balance between cellular aerobic and anaerobic metabolism and is a sensitive marker of brain energy dysfunction, specifically glucose metabolism, when it is increased in humans. 50 In addition, an increased LPR has been associated with poor outcome in SAH. 41, 51 Several CMD studies have demonstrated that changes in CMD values may assist in the diagnosis of vasospasm 12, 41 and that an abnormal pattern may be identified several hours before delayed neurological deficits are clinically apparent. 52, 53 Other studies suggest that CMD may help guide established therapies, including CPP targets, 54 hyperventilation, 55 glucose control, 56, 57 transfusion, 58 and hypertonic saline. 59 Our study suggests that PBTO 2 and CMD monitors may detect episodes of compromised brain function that may otherwise go undetected when only ICP and CPP are monitored in SAH. Furthermore, this compromise may be independent of vasospasm. This is an important finding because secondary cerebral insults that can have an adverse effect on outcome may be preventable with multimodality monitoring. Furthermore, the combination of PBTO 2 electrodes and CMD can help differentiate hypoxic and nonhypoxic patterns of cellular dysfunction, which could allow more targeted therapies to be instituted. Because changes in the LPR may precede the onset of neurological deficits, multimodal monitoring also could help widen the therapeutic window, permitting the treatment of secondary cerebral insults while they are still in a reversible stage.
Study Limitations
There are several limitations to this study. First, although the patients were enrolled in a prospective microdialysis study, the data were obtained and analyzed in a retrospective manner. This methodology may have introduced bias into our results. Second, our results may lack external validity because the study was conducted at a single center. Third, the number of patients studied was small, and thus our results and conclusions should be considered preliminary. However, we examined multiple physiological variables and corresponding CMD and PBTO 2 values from more than 2000 samples of data. Fourth, the monitors that we used sampled a limited volume of local tissue. It is not clear that these local measurements reflect the global status of the brain. Whether deliberate ''penumbral'' targeting of the monitors would have altered our findings is unknown. In addition, we were not able to correct our findings for the presence or absence of vasospasm because only 10 patients underwent angiography during the period of CMD, and 9 of these patients had no or mild angiographic vasospasm. Future studies will need to further address the precise location of PBTO 2 and CMD monitors and its effect on CBF, cerebral metabolic rate of oxygen consumption, and outcome findings. Fifth, this study is not a pure observational study because patients received targeted interventions for abnormal ICP, CPP, and PBTO 2 . Sixth, microdialysis samples need to be collected hourly; these hourly samples were compared with hourly averages of other physiological variables, an approach that may have missed subtle or intermittent abnormalities. Finally, our microdialysis analysis was limited to brain glucose metabolism. Further studies could investigate the role of brain tissue glycerol as a marker of cell membrane damage and extracellular glutamate as a marker for excitotoxicity.
Implications of This Study
Because the current study is small and observational, we cannot make any definitive statements. However, the results of this study should provoke questions and generate hypotheses about several concepts in SAH care. In particular, although it is important to monitor for and manage ICP and vasospasm, our results imply that perhaps we should monitor for cellular health or dysfunction. This strategy may allow the identification of pathological processes other than reduced blood flow (ie, vasospasm) or changes in the brain before an increase in ICP occurs. 29, 60 Microdialysis and positron emission tomography findings in TBI support this approach. 24, 28 Furthermore, the concept of what actually constitutes vasospasm and how best to define ischemia after SAH are being reevaluated, 61, 62 given the results of some trials in which clinical outcome did not improve despite reduced vessel narrowing. [63] [64] [65] This dissociation between vasospasm and clinical outcome has refocused efforts on limiting brain injury and DCI in general rather than just preventing vessel narrowing associated with vasospasm. Although cerebral ischemia and infarction may occur with angiographic evidence of vessel narrowing, each may occur independently of the other because there are multiple factors other than vasospasm that potentially contribute to DCI. [66] [67] [68] [69] Consequently, we believe that rather than focusing on vessel diameter, emphasis should be placed on what happens to the brain itself.
Vasospasm is but one of many causes, including several nonischemic ones, of cerebral energy dysfunction. For example, an increased LPR may be observed in thiamine deficiency for 77 and hyperventilation-induced respiratory alkalosis. 78, 79 In no way do our results suggest that ICP and vasospasm are not important in the management of SAH. Instead, they imply that it may be important to search for alternative reasons for cerebral compromise in some patients.
CONCLUSION
The main findings of this study suggest that conventional ICP and CPP monitoring in poor-grade aneurysmal SAH patients may not reliably detect all episodes of cerebral dysfunction or compromise. Conversely, increased ICP and decreased CPP can occur in the absence of abnormal brain oxygen tension or cerebral metabolism. These observations emphasize the need for multimodality monitoring in comatose SAH patients. One monitor is clearly not superior to another. Rather, each monitoring technique provides information on a different facet of patient physiology. Further research on multimodality monitoring should focus on integrating data from different monitors to identify different patterns of cerebral dysfunction and determine the clinical and prognostic implications of these patterns. A better understanding of cerebral dysfunction after SAH may have profound therapeutic implications in poor-grade SAH patients and may allow better targeted therapy.
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